Evidence map›Paper›PMID 30176077›Full record

SynthesisAddiction (Abingdon, England)2019

Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory? A systematic narrative review and thematic synthesis of the qualitative literature.

Amy O'Donnell, Michelle Addison, Liam Spencer, Heike Zurhold, Moritz Rosenkranz, Ruth McGovern, Eilish Gilvarry, Marcus-Sebastian Martens, Uwe Verthein, Eileen Kaner

Abstract readSystematic Review
In one paragraph

Synthesis in Addiction (Abingdon, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amy O'DonnellInstitute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0003-4071-9434
Michelle AddisonInstitute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
Liam SpencerInstitute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
Heike ZurholdCentre of Interdisciplinary Addiction Research of Hamburg University, Department of Psychiatry, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Moritz RosenkranzCentre of Interdisciplinary Addiction Research of Hamburg University, Department of Psychiatry, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Ruth McGovernInstitute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
Eilish GilvarryInstitute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
Marcus-Sebastian MartensCentre of Interdisciplinary Addiction Research of Hamburg University, Department of Psychiatry, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Uwe VertheinCentre of Interdisciplinary Addiction Research of Hamburg University, Department of Psychiatry, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Eileen KanerInstitute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.

Funding

Department of Health [UK] ST‐0416‐1000Medical Research Council MR/K02325X/1
6 · The paper itself

Abstract

BACKGROUND AND

aimsThere is limited evidence on what shapes amphetamine-type stimulant (ATS) use trajectories. This systematic narrative review and qualitative synthesis aimed to identify individual, social and environmental influences shaping key phases in the ATS use trajectory: initiation, continuation, increase/relapse and decrease/abstinence.

methodsMEDLINE, PsycINFO, EMBASE, and PROQUEST (social science premium collection) were searched from 2000 to 2018. Studies of any qualitative design were eligible for inclusion. Extracted data were analysed according to four key phases within drug pathways, and then cross-analysed for individual, social and environmental influences.

resultsForty-four papers based on 39 unique studies were included, reporting the views of 1879 ATS users. Participants were aged 14-58 years, from varied socio-economic and demographic groups, and located in North America, Europe, Australasia and South East Asia. Reasons for initiation included: to boost performance at work and in sexual relationships, promote a sense of social 'belonging' and help manage stress. Similar reasons motivated continued use, combined with the challenge of managing withdrawal effects in long-term users. Increased tolerance and/or experiencing a critical life event contributed to an increase in use. Reasons for decrease focused on: increased awareness of the negative health impacts of long-term use, disconnecting from social networks or relationships and financial instability.

conclusionsAmphetamine-type stimulant users are a highly diverse population, and their drug use careers are shaped by a complex dynamic of individual, social and environmental factors. Tailored, joined-up interventions are needed to address users' overlapping economic, health and social care needs in order to support long-term abstinence.

Indexed as

Amphetamine-Related DisordersDisease ProgressionHumansMethamphetamineMotivationN-Methyl-3,4-methylenedioxyamphetaminePeer GroupQualitative ResearchRisk FactorsSexual BehaviorSocial BehaviorSocial EnvironmentMethamphetamineN-Methyl-3,4-methylenedioxyamphetamineAmphetamine-related disordersamphetamine-type stimulantsdrug use trajectorylife coursequalitative synthesissystematic review

Identifiers

PMID30176077
PMCPMC6519251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.